PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies
Summary
CAMARILLO, Calif.--(BUSINESS WIRE)--Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. PBS Biotech utilizes proprietary Vertical-WheelTM technology to achieve unique mixing properties and environmental conditions for cell therapy products, which have proven superior to traditional “stirred-tank” bioreactors in multiple published studies. With the support of BroadOak, PBS Biotech will deliver on our vision of becoming the world’s standard manufacturing platform for allogeneic cell therapies, starting with a full line of GMP-qualified bioreactor systems to support the clinical studies and commercialization needs of our customers.” PBS Biotech systems are used by over 200 customers ranging from small-scale research and development groups to large-scale manufacturing groups. PBS Biotech will look to secure and expand its product line over the next several years to support existing and future customers through clinical trials to commercialization. PBS Bioreactors utilize proprietary “Vertical-WheelTM” technology to support shear sensitive cell therapy products and offer unmatched scale up capabilities.